Elyxium Wealth’s Corcept Therapeutics CORT Stock Holding History

Elyxium Wealth’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24	Closed	-$836	–	389
2025 Q4	$836	Buy	+24	New	+$1.89K	﹤0.01%	1215

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Elyxium Wealth's CORT Position: Q1 2026 in Review

Elyxium Wealth sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 24 shares — an estimated $836 sold.

Elyxium Wealth first reported a position in CORT in Q4 2025 and held it in 1 quarter. The position peaked at $836 in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Elyxium Wealth reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 24 Corcept Therapeutics shares in Q1 2026, an estimated $836.
Elyxium Wealth first reported a position in Corcept Therapeutics in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's Corcept Therapeutics position peaked at $836 in Q4 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.